CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Símbolo de cotizaciónCRVO
Nombre de la empresaCervoMed Inc
Fecha de salida a bolsaNov 09, 2016
Director ejecutivoAlam (John J)
Número de empleados15
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección20 Park Plaza, Suite 424
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02116
Teléfono16177444400
Sitio Webhttps://cervomed.com/
Símbolo de cotizaciónCRVO
Fecha de salida a bolsaNov 09, 2016
Director ejecutivoAlam (John J)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos